We are updating our Privacy Policy and Terms and Conditions to help you clearly understand how your personal information is collected, stored and managed. Learn More
Menu Back toSession-7-Patient-s-Role-in-the-Regulatory-and-HTA-Process

Value, Access and Regulatory Strategy Workshop


Session 7: Relative Efficacy versus Relative Effectiveness – the Future

    Session Chair(s)
      François  Meyer, MD

      François Meyer, MD

      • Advisor to the President, International Affairs
      • French National Authority for Health (HAS), France
    • Current challenges in the assessment of relative efficacy/effectiveness
    • The need for comparative data
    • Role of EUnetHTA moving forward
    • Cooperation between EMA and EUnetHTA: current status and perspectives
    Speaker(s)
      Leeza  Osipenko, PhD, MSc

      Leeza Osipenko, PhD, MSc

      • Head of Scientific Advice
      • National Institute for Health and Care Excellence (NICE), United Kingdom
      Kristin  Svanqvist, MPharm

      Kristin Svanqvist, MPharm

      • Head of Unit for HTA and Reimbursement
      • Norwegian Medicines Agency (NoMA), Norway
      Michael  Berntgen, PhD

      Michael Berntgen, PhD

      • Head of Product Development Scientific Support Department
      • European Medicines Agency, European Union, United Kingdom